Surface Oncology to Participate in the Gilmartin Group Emerging Growth Company Showcase

Rhea-AI Summary

Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company, announced that CEO Rob Ross will participate in a fireside chat at the Gilmartin Group Emerging Growth Company Showcase on August 31, 2022, at 2:30 p.m. ET. The event will be available via a live webcast on the Surface Oncology website, with a replay accessible afterward. Surface is focused on developing next-generation therapies targeting the tumor microenvironment, with clinical-stage programs for CD39 and IL-27, and partnerships with Novartis and GlaxoSmithKline.

CAMBRIDGE, Mass., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Rob Ross, M.D., chief executive officer, will participate in a fireside chat at the virtual Gilmartin Group Emerging Growth Company Showcase on Wednesday, August 31, 2022 at 2:30 p.m. ET.

A live webcast of the presentation may be accessed by visiting the Investors & Media section of the Surface Oncology website at https://investors.surfaceoncology.com/. In addition, a replay of the webcast will be available on the company’s website following the presentation.

About Surface Oncology
Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment. Its pipeline includes two wholly-owned clinical-stage programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on selectively depleting regulatory T cells in the tumor microenvironment via targeting CCR8 (SRF114). In addition, Surface has two partnerships with major pharmaceutical companies: a collaboration with Novartis targeting CD73 (NZV930; Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (GSK4381562, formerly SRF813; Phase 1). Surface’s novel, investigational cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response and may be used alone or in combination with other therapies. For more information, please visit www.surfaceoncology.com.

Contact
Scott Young
(617) 865-3250
syoung@surfaceoncology.com

FAQ

What is the date of the upcoming event for Surface Oncology?

The upcoming event for Surface Oncology is on August 31, 2022.

Who is participating in the Gilmartin Group Emerging Growth Company Showcase?

CEO Rob Ross of Surface Oncology will participate in the showcase.

Where can I access the webcast of the Surface Oncology event?

The webcast of the Surface Oncology event can be accessed on their Investors & Media section of their website.

What is the primary focus of Surface Oncology's research?

Surface Oncology focuses on developing next-generation immunotherapies targeting the tumor microenvironment.

Does Surface Oncology have any partnerships with pharmaceutical companies?

Yes, Surface Oncology has partnerships with Novartis and GlaxoSmithKline.